India prioritises GMP enforcement and biopharma push to protect pharmacy-of-the-world status
Pharma Secretary Manoj Joshi flagged mandatory Revised Schedule M compliance, stronger quality surveillance, possible trade-margin reforms and domestic API incentives. The government is also weighing a ₹10,000-crore biopharma mission, with implications for medicine availability, pricing and retail pharmacy supply.
What happened
Department of Pharmaceuticals, Government of India · India’s pharma secretary outlined stricter GMP enforcement, potential trade-margin reforms and domestic API
Key facts
- Revised Schedule M mandatory from January 1
- Essential-drug prices cannot rise by more than 10% annually
- Around 80% of medicines are outside price control
- 30–35% of drugs depend on imports from China
- 60–65% of drugs have an entirely domestic value chain
- Four or five companies produce GLP-1 medicines in India
- ₹10,000-crore proposed biopharma mission
Why this matters
Strategic buyers should prioritise GMP-ready manufacturing, domestic API capabilities and biopharma assets that can benefit from government incentives and a more quality-led supply chain.
What to watch
- Formal notification of Revised Schedule M deadlines, exemptions, phased implementation rules and penalties for non-compliance.
- State and central inspection intensity, warning letters, license suspensions, product recalls and batch-level quality alerts.
- Evidence of production cuts or price-increase requests from MSME pharmaceutical manufacturers.
- Announcements on trade-margin caps, margin rationalization, distributor compensation or changes to the Drug Price Control Order framework.
- Cabinet approval, funding structure, target modalities and implementation agency for the proposed ₹10,000-crore biopharma mission.
- New API production-linked incentives, bulk-drug park utilization, import-duty changes and procurement preferences for domestic inputs.
- Wholesale stock-out frequency and retailer substitution rates for essential generic categories.
- Map exposure to manufacturers with known Schedule M upgrade needs, particularly suppliers of high-velocity essential generics and narrow-source products.
- Build alternative sourcing and safety-stock plans for molecules likely to be disrupted by plant remediation, license suspensions or supplier exits.
- Track supplier quality credentials as a procurement criterion, including inspection history, product recalls, batch rejection rates and Revised Schedule M readiness.
- Prepare for manufacturer price-revision requests and reassess pharmacy gross-margin assumptions if trade-margin reform advances.
- Expand cold-chain, specialty dispensing and patient-support capabilities in markets where biosimilars and complex biologics could become more accessible.
- Prioritize distributor partnerships with strong traceability, recall execution and multi-supplier inventory visibility.